Ultrasonographic frequency of complex aortic plaques in patients with atrial fibrillation Authors: Atilla Bulut, Fadime Koca, Yurdaer Donmez, Hilmi Erdem Sumbul, Mustafa Lütfullah Ardıç, Mevlut Koc Published: 2026 ABSTRACT AbstractBackgroundThe presence of aortic plaque is an important risk factor for stroke in patients with atrial fibrillation (AF). A history of vascular disease, defined as the presence of complex aortic plaque (CAP), constitutes one of the components of the CHA₂DS₂-VA score. However, data regarding the frequency of abdominal aortic (AA) plaques in patients with AF are limited in the literature. Therefore, the present study aimed to investigate the prevalence of AA–CAP and its associated parameters in patients with AF.MethodA total of 748-patients with AF who underwent abdominal ultrasonography (US) for aortic plaque assessment were included in this study. In addition to routine clinical evaluations, all patients were assessed for the presence of AA–CAP using US. The study population was subsequently divided into two groups according to the presence or absence of AA–CAP.ResultAA–CAP was detected in 106 (14.2%) of the AF patients included in the study. Patients with AA-CAP were older and had higher CHA₂DS₂-VA scores and a greater burden of cardiovascular risk factors. In addition, blood pressure levels and glucose, urea, and creatinine values were higher, whereas hemoglobin levels were lower in patients with AA–CAP. In logistic regression analysis, age, CHA₂DS₂-VA score, and the presence of hypertension were found to be independently associated with AA–CAP (OR = 1.071,95%CI:1.031–1.111,p < 0.001;OR = 2.446,95%CI:1.900–3.149,p < 0.001;OR = 2.735,95%CI:1.441–5.190,p = 0.002). ROC curve analysis demonstrated that age and CHA₂DS₂-VA score, with cut-off values of 65 years and 3, respectively, identified the presence of AA–CAP with acceptable sensitivity and specificity.ConclusionAA–CAP was observed at a considerable rate (14.2%) in patients with AF. Therefore, in AF patients without previously known coronary or peripheral arterial disease, assessment of AA–CAP using abdominal US may be useful for stroke risk stratification and for more accurate calculation of the CHA₂DS₂-VA score.Keywords: Atrial fibrillation, Aortic plaque, Abdominal ultrasonography Introduction Atrial fibrillation (AF) remains the most common sustained arrhythmia and is a major cause of cardiovascular morbidity and mortality [1]. In patients with AF, the CHA₂DS₂-VA score is widely used for stroke risk stratification. One of the major components of the CHA₂DS₂-VA score is the presence of vascular disease, which is defined as coronary artery disease (CAD) or peripheral vascular disease (PVD). The presence of CAD is defined as: (i) a history of myocardial infarction, (ii) angina pectoris, (iii) a history of coronary revascularization (surgical or percutaneous), or (iv) significant CAD detected by coronary angiography or cardiac imaging [1]. PVD is defined by: (i) intermittent claudication, (ii) prior revascularization for peripheral vascular disease, (iii) percutaneous or surgical intervention involving the abdominal aorta (AA), or (iv) the presence of complex aortic plaque (CAP), defined as plaques with mobility, ulceration, pedunculation, or a thickness ≥ 4 mm on imaging [1, 2]. Therefore, assessment of CAP, which is often asymptomatic, is particularly important in AF patients without a clinical history or symptoms of vascular disease. Previous studies have shown that the prevalence of CAP increases with age and is more common in patients with hypertension (HT) and diabetes mellitus (DM) [3–9]. An association between aortic plaque and the development of AF has been demonstrated, and CAP has been reported to be more prevalent in patients with AF [3–6]. The prevalence of CAP detected by transesophageal echocardiography (TOE) in patients with AF has been reported to range from 8.3% to 38.7% [3–6]. However, in daily clinical practice, CAP is often insufficiently evaluated during calculation of the CHA₂DS₂-VA score, which guides the initiation of oral anticoagulant (OAC) therapy. Failure to perform TOE, cardiovascular computed tomography (CCT), or cardiovascular magnetic resonance (CMR) imaging may result in missed CAP, leading to underestimation of the CHA₂DS₂-VA score and, consequently, inappropriate withholding of anticoagulant therapy. A major reason for this limitation is the lack of simple, inexpensive, repeatable, and practical diagnostic tools for routine assessment of CAP. Due to the high incidence of atherosclerotic plaques and thrombi in the AA, CCT or CMR imaging has been recommended for evaluation [2]. Although CT and MR are primarily suggested for assessment of the thoracic aorta, the aortic root may be evaluated by transthoracic echocardiography (TTE), while the ascending, arch, and descending aorta can be assessed using TOE [2, 10]. To the best of our knowledge, there are no data in the literature, clinical guidelines, or routine practice regarding the evaluation of atherosclerotic plaques in the AA using ultrasonography (US). Moreover, no study has specifically investigated the frequency of AA–CAP in patients with AF. Nevertheless, previous studies have reported AA intima–media thickness measurements in certain specific disease populations [11–13]. In the present study, we aimed to investigate the frequency of AA–CAP and the parameters associated with AA–CAP in patients with AF without known CAD or PVD. Materials and methods Study population This retrospective observational cohort study included patients who presented to the Arrhythmia Outpatient Clinic of our hospital with a diagnosis of AF between January 1, 2020, and January 1, 2026, and who underwent abdominal US for evaluation of CAP. The diagnosis of AF was established by 12-lead surface electrocardiography performed at the time of Arrhythmia Outpatient Clinic. Patients with previously known CAD or PVD, obesity, a history of abdominal aortic surgery, AA aneurysm, severe hepatic or renal disease, malignancy, active infection, moderate to severe aortic or mitral valve disease were excluded from the study. The requirement for informed consent was waived due to the retrospective nature of the study; therefore, informed consent was not obtained from the patients included in the study. The study protocol was approved by the Clinical Research Ethics Committee of Adana City Hospital. A detailed medical history was obtained from each patient, and comprehensive physical examinations were performed. Heart rate and blood pressure measurements were recorded. Concomitant cardiac and non-cardiac systemic diseases were documented. Blood biochemistry and complete blood count analyses were performed for all patients. Biochemical parameters included glucose, urea, creatinine, sodium, potassium, total cholesterol, triglycerides, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol levels. In addition, complete blood count parameters, including white blood cell count, hemoglobin level, and platelet count, were recorded. After assessment of AA-CAP presence, the CHA₂DS₂-VA score was calculated by evaluating each of the previously defined parameters individually, in accordance with the 2024 European Society of Cardiology (ESC) guidelines for atrial fibrillation [1]. The study flowchart is shown in Fig. 1. Flowchart of the study Identification of patients with atrial fibrillation AF was diagnosed on 12-lead ECG based on the following criteria: (i) irregular atrial activity with variable atrial cycle length (< 200 ms), (ii) irregular R–R intervals, (iii) absence of distinct and repetitive P waves, (iv) presence of rapid, irregular fibrillation waves with variable morphology and amplitude instead of P waves, and (v) an irregular and variable ventricular rate. In addition to 12-lead ECG, AF was also diagnosed when similar findings persisted for more than 30 s on single-lead ECG recordings or Holter ECG monitoring [1]. Detection of complex aortic plaques by abdominal ultrasonography Abdominal aortic examination was performed in the supine position using a high-resolution ultrasound system (Philips EPIQ 7) equipped with a 5-MHz convex transducer (Philips Health Care, Bothell, WA, USA). The assessment of AA-CAP presence is routinely performed using abdominal US according to a standardized protocol. The AA was evaluated from the level of the renal artery bifurcation to the level of the iliac artery bifurcation. The presence of aortic plaques was determined by measurements obtained from plaques located on the posterior wall of the AA. The aorta was examined in both longitudinal and transverse planes. Longitudinal scanning was performed to optimize visualization of plaques on the posterior or far arterial wall. Plaque mobility was assessed using B-mode (2D) dynamic real-time imaging, and in cases where mobility was detected, video recordings were obtained and subsequently evaluated using cine-loop review. Except plaque mobility, other measurements were obtained on frozen images, and the two highest-quality images were selected for analysis in each subject. Plaque thickness was defined as the distance between the leading edge of the first echogenic line and the leading edge of the second echogenic line. The first line represents the intima–lumen interface, while the second line corresponds to the collagen-containing upper layer of the adventitia. Vascular plaques were measured using ultrasonic calipers by two independent observers who were blinded to the clinical data. Plaque thickness values were calculated as the mean of six individual measurements. After completion of the examinations, plaques exhibiting mobility, ulceration, pedunculation, or a thickness ≥ 4 mm were classified as CAP (Fig. 2) [1, 2]. B-mode ultrasonographic images of atrial fibrillation patients demonstrating complex aortic plaques located on the posterior wall of the abdominal aorta. A Dynamic real-time B-mode imaging showing a complex aortic plaque with mobility and pedunculation. B Frozen B-mode ultrasonographic image demonstrating a complex aortic plaque with a thickness ≥ 4 mm Statistical analysis Variables were classified as categorical or continuous. Categorical variables were expressed as numbers and percentages and compared using the chi-square test. The kappa coefficient was used to assess interobserver and intraobserver variability of US parameters. Continuous variables were expressed as mean ± standard deviation (SD). The normality of continuous variables was evaluated using the Kolmogorov-Smirnov test. Normally distributed continuous variables were compared using the independent samples Student’s t test, whereas non-normally distributed variables were compared using the Mann–Whitney U test. Forward stepwise multivariate logistic regression analysis was performed to identify independent predictors of CAP, and variables independently associated with CAP were determined. Receiver operating characteristic (ROC) curve analysis was conducted for variables independently associated with CAP, and sensitivity and specificity values were calculated for each parameter to assess their predictive ability. The optimal cut-off value was determined based on the maximal Youden index. All statistical analyses were performed using IBM SPSS Statistics version 23.0 (SPSS Inc., Chicago, IL, USA), and a p value < 0.05 was considered statistically significant. Results After application of the exclusion criteria, a total of 748 patients (406 men and 342 women; mean age 59.4 ± 12.4 years) were included in the study. Of the patients screened for eligibility, 104 were excluded based on the predefined exclusion criteria. These included 50 patients with a history of coronary artery disease or peripheral arterial disease, 39 patients with obesity, 5 patients with a history of AA surgery or AA aneurysm, 3 patients with severe hepatic or renal dysfunction, and 7 patients with moderate-to-severe aortic or mitral valvular disease. In the AF population included in our study, the prevalence of AA–CAP was found to be 14.2%. Patients were divided into two groups according to the presence or absence of AA–CAP, and all clinical, laboratory, and imaging parameters were compared between the groups. Parameters associated with the presence of AA–CAP were subsequently identified. Cohen kappa values that evaluate the inter-intraobserver variability were over 90% for all Doppler US parameters (p < 0.001 for all comparisons). In our study, 14 patients (1.87%) exhibited isolated AA-CAP in the absence of other CHA₂DS₂-VA score components. In these patients, the presence of AA-CAP resulted in a CHA₂DS₂-VA score of 1. Comparison of study parameters between patients with and without aortic plaque When the clinical, demographic, and laboratory characteristics of patients with and without AA–CAP were compared, patients with AA–CAP were significantly older and had higher systolic and diastolic blood pressure values. In addition, the prevalence of HT, DM, heart failure (HF), and cerebrovascular events was higher in the AA–CAP group. Patients with AA–CAP also had higher glucose, blood urea nitrogen, creatinine, and CHA₂DS₂-VA scores, whereas hemoglobin levels were significantly lower. All other variables were comparable between the two groups (Table 1). Table 1Comparison of study parameters between patients with and without aortic plaquePatients with aortic plaquen = 106Patients without aortic plaquen = 642 p Age (year)70.5 ± 7.957.5 ± 11.3< 0.001Sex (Female/Male), n (%)51 (48%) / 55(52%)291 (45%) / 351 (55%)0.594Systolic blood pressure (mmHg)131 ± 16126 ± 14 0.015 Diastolic blood pressure (mmHg)79 ± 1175 ± 10 0.003 Heart rate (pulse/min)81 ± 1080 ± 9.50.558CHA2DS2-VA score (n)3.55 ± 1.741.32 ± 1.21 < 0.001 Body mass index (kg/m2)28.3 ± 4.926.9 ± 5.10.822Diabetes, n (%)55 (52%)141 (22%) < 0.001 Hypertension, n (%)75 (71%)326 (51%) < 0.001 Cerebrovascular event, n (%)8 (8%)7 (1%) < 0.001 Heart failure, n (%)30 (28%)45 (7%) < 0.001 Glucose (mg/dL)129 ± 67110 ± 42 0.004 White blood cell (µL)7.82 ± 2.67.69 ± 3.40.764Hemoglobin (g/dL)12.9 ± 1.813.4 ± 1.4 0.005 Platelet (µL)233 ± 64248 ± 790.512Urea (mg/dL)37.7 ± 19.528.4 ± 10.4 0.002 Creatinine (mg/dL)0.95 ± 0.470.76 ± 0.19 < 0.001 Sodium (mmol/L)139 ± 3.1140 ± 3.90.308Potassium (mmol/L)4.30 ± 0.54.29 ± 0.60.512Total cholesterol (mg/ dL)183 ± 49189 ± 490.239LDL-cholesterol (mg/dL)124 ± 30127 ± 340.349HDL-cholesterol (mg/dL)49 ± 1450 ± 140.469Triglyceride (mg/dL)167 ± 100162 ± 1080.631LDL Low density lipoprotein, HDL High density lipoprotein Comparison of study parameters between patients with and without aortic plaque LDL Low density lipoprotein, HDL High density lipoprotein Factors independently associated with aortic plaque presence When parameters found to be significant in univariate analysis were evaluated using multivariate regression analysis, only age, CHA₂DS₂-VA score, and the presence of HT remained independently associated with the presence of AA–CAP. According to this analysis, each 1-point increase in the CHA₂DS₂-VA score was associated with a 2.45-fold increase in the likelihood of AA–CAP. Similarly, the presence of HT was associated with a 2.75-fold higher likelihood of AA–CAP. In addition, each 1-year increase in age was associated with a 7.1% increase in the risk of AA–CAP (Table 2). For regression model, multicollinearity was assessed using variance inflation factor (VIF) values. All VIF values were below 2, indicating a low degree of multicollinearity. Table 2Independent predictors of aortic plaque identified by regression analysisOdds Ratio95% CI p Age (each 1 year)1.0711.031–1.111< 0.001Systolic blood pressure (mmHg)0.9970.976–1.0180.771Diastolic blood pressure (mmHg)0.9950.967–1.0240.741CHA2DS2-VA score (each 1)2.4461.900–3.149 < 0.001 Diabetes (presence)1.2040.572–2.5340.625Hypertension (presence)2.7351.441–5.190 0.002 Cerebrovascular event (presence)1.1780.542–2.6340.712Heart failure (presence)1.4430.587–3.5460.425Glucose (each mg/dL)0.9970.989–1.0040.374Hemoglobin (each g/dL)1.1560.955–1.4000.137Urea (each mg/dL)1.0060.988–1.0260.505Creatinine (each mg/dL)1.9931.012–3.9240.054 Independent predictors of aortic plaque identified by regression analysis ROC analysis for the detection of aortic plaque Receiver operating characteristic (ROC) curve analysis performed to assess the ability of age and CHA₂DS₂-VA score to detect the presence of AA–CAP demonstrated that the areas under the ROC curve were 0.842 for age and 0.852 for the CHA₂DS₂-VA score, both of which were statistically significant (p < 0.001; Fig. 3). Receiver operating characteristic curves and cut-off levels for age and CHA2DS2-VA score in predicting complex aortic plaque A CHA₂DS₂-VA score cut-off value of 3 predicted the presence of AA–CAP with a sensitivity of 86% and a specificity of 85%. Similarly, an age cut-off value of 65 years predicted the presence of AA–CAP with a sensitivity of 84% and a specificity of 78% (Fig. 3). Discussion The major findings of the present study can be summarized as follows: (i) The prevalence of AA–CAP in patients with AF was 14.2%. Although data on AA–CAP in AF patients are lacking in the literature, this prevalence is comparable to previously reported rates of CAP detected in the thoracic aorta. (ii) Approximately 1.87% of patients exhibited isolated AA-CAP in the absence of other CHA₂DS₂-VA score components. (iii) Although several parameters were associated with AA–CAP in AF patients, age, CHA₂DS₂-VA score, and the presence of HT were independently associated with CAP; to the best of our knowledge, this finding has been demonstrated for the first time. (iv) Each 1-point increase in the CHA₂DS₂-VA score increased the likelihood of AA–CAP by 2.45-fold, the presence of HT increased the likelihood by 2.75-fold, and each 1-year increase in age was associated with a 7.1% increase in AA–CAP risk. (v) Based on our findings, the presence of AA–CAP detectable by US should be taken into consideration when calculating the CHA₂DS₂-VA score in patients with AF. The incidence of atheromatous disease in the aorta has been reported to range from 40% to 51.3%, typically developing early in life. Most cases remain asymptomatic, with only 7.6% becoming complicated [2]. In particular, CAP with a thickness ≥ 4 mm located in the aortic arch or ascending aorta has been shown to be associated with cerebrovascular events [1, 2]. In patients with CAP, statin therapy and single antiplatelet therapy (clopidogrel or low-dose aspirin) are recommended to reduce cardiovascular events, whereas OAC and dual antiplatelet therapy are not recommended [2]. The reported prevalence of CAP varies widely depending on patient characteristics, underlying diagnoses, risk factors, diagnostic modalities, and the anatomical segments of the aorta evaluated, ranging from 0% to 44.4% [14]. In a study evaluating 770 AF patients using TOE—a cohort comparable in size to ours—the prevalence of thoracic aortic CAP was 25%, with rates of 2%, 11%, and 21% in the ascending, transverse, and descending aorta, respectively [6]. In another study involving AF patients, CAP prevalence was reported as 8.3% [4]. In a prospective multicenter study by Nicot et al. [3] that included 1,479 patients with acute cerebral ischemia, the prevalence of CAP was 14.6%. In contrast to previous studies, our study specifically evaluated AA–CAP in AF patients and demonstrated a prevalence of 14.2%, comparable to the findings reported by Nicot et al. [3]. CAP is a frequent cause of ischemic stroke, and TOE remains the most used diagnostic modality for its detection [7–16]. Numerous clinical, demographic, and laboratory parameters have been associated with CAP, including age, male sex, HT, DM, HF, prior cerebrovascular events, AF, smoking, aortic valve sclerosis, mitral annular calcification, serum creatinine levels, CHA₂DS₂-VA score, and the presence of CAD [3–9, 17]. In the present study, age, the presence of HT, and CHA₂DS₂-VA score were identified as independent predictors of AA–CAP. Several studies have demonstrated an independent association between CHA₂DS₂-VA score and CAP [3, 4, 18], and our findings are consistent with these reports. In a study by Yang et al. [4], a CHA₂DS₂-VA score ≥ 2 was associated with a 3.23-fold increase in CAP risk. Similarly, Nicot et al. [3] demonstrated that the CHA₂DS₂-VA score independently predicted CAP presence beyond other cardiovascular risk factors and reported that a CHA₂DS₂-VA score < 2 had a negative predictive value of 96% for thoracic aortic CAP, suggesting its utility in excluding CAP. In line with previous studies, our results showed that each 1-point increase in the CHA₂DS₂-VA score increased the risk of AA–CAP by 2.45-fold. Furthermore, a CHA₂DS₂-VA score cut-off value of 3 predicted AA–CAP with a sensitivity of 86% and a specificity of 85%. Advanced age is one of the most important and independent risk factors for CAP [1–4, 7, 9]. Yang et al. [4] reported that each 1-year increase in age was associated with a 6.7% increase in CAP risk. Consistent with this finding, our study demonstrated that each 1-year increase in age increased the risk of AA–CAP by 7.1%. In addition, Agmon et al. [9] reported that HT was independently associated with CAP and increased CAP risk by 2.37-fold. Similarly, our findings showed that the presence of HT independently predicted AA–CAP and increased its likelihood by 2.74-fold. To the best of our knowledge, there are no studies in the literature investigating the presence of CAP in the absence of CHA₂DS₂-VA score components. In our study, AA–CAP was identified in 14 patients (1.87%) with a CHA₂DS₂-VA score of 0. While these patients would not ordinarily be considered for oral OAC therapy in the absence of AA–CAP, the presence of AA–CAP increases their CHA₂DS₂-VA score to 1, thereby potentially indicating the need for OAC therapy in accordance with current guideline recommendations [1]. Although this represents a relatively small proportion of patients, it constitutes a clinically important and sensitive finding. Assessment of AA–CAP by abdominal US is not routinely performed by all clinicians. However, some physicians may request abdominal US examinations before interventional procedures, such as coronary angiography, AF ablation, and transcatheter aortic valve implantation. Evaluation of the AA is a routine component of abdominal US, and AA–CAP can be identified during this assessment. Several centers have substantial experience in the evaluation of AA-IMT and AA–CAP in adult populations, and multiple studies have been published on this topic [11–13]. The clinical management of patients with AA-CAP remains at the discretion of the treating physician, and no standardized additional diagnostic evaluation is routinely performed solely based on the detection of AA–CAP. Nevertheless, greater attention may be warranted during interventional procedures because of the potential risk of peripheral vascular complications, and closer post-procedural monitoring for peripheral embolic events may be considered. In addition, optimization of cardiovascular preventive therapy, including statin therapy and single antiplatelet therapy, may be appropriate in selected patients. Furthermore, the presence of AA-CAP may influence decisions regarding OAC therapy in carefully selected patients with AF, particularly those with a CHA₂DS₂-VA score of 0 [1, 2]. Atherosclerosis is known to begin early in life, initially manifesting as fatty streaks within the AA. In the present study, the detection of AA–CAP was considered evidence of underlying vascular disease. Therefore, we hypothesized that the presence of AA–CAP could indirectly contribute to thromboembolic risk assessment through the vascular disease component of the CHA₂DS₂-VA score [1]. However, in the absence of longitudinal follow-up data, it would not be appropriate to conclude that AA–CAP is directly associated with future stroke events. Importantly, the CHA₂DS₂-VA score is used not only to estimate the risk of stroke but also the risk of systemic and peripheral thromboembolic events. Therefore, clinically relevant outcomes such as peripheral embolism and acute limb ischemia should also be considered when interpreting the potential significance of AA–CAP [1, 2]. Limitations The present study has several important limitations. First, this was a single-center, non-randomized, retrospective study conducted in a relatively small patient population from a single ethnic region. Additionally, the fact that the study was not conducted in all patients with AF but rather in a selected population may introduce selection bias and affect the representativeness of the study cohort. Therefore, prospective, randomized, multicenter studies including larger populations and diverse ethnic backgrounds are required to validate our findings. Second, although an association between CAD and CAP has been well established [17], patients with previously known CAD were excluded from our study. Inclusion of such patients might have influenced the results. In addition, the presence of CAP has been shown to predict long-term cardiovascular events in patients with AF [19]. However, due to the absence of longitudinal follow-up in our study, we were unable to evaluate long-term outcomes, including mortality and morbidity. In the absence of longitudinal follow-up data demonstrating that AA–CAP predicts future cardiovascular events, the clinical significance of the present findings remains uncertain, and the study should be regarded as hypothesis-generating. We believe that such analyses may be feasible in future studies with extended follow-up. We did not assess the potential impact of medical therapy or ablation treatment on CAP presence or clinical outcomes in this patient population [20]. Evaluation of these factors might have provided additional clinically relevant insights and strengthened the overall significance of our findings. Obesity is a well-established risk factor for the development of atrial fibrillation (AF), and its prevalence is increased in obese individuals [1]. In addition, obesity is an important risk factor for atherosclerosis and, consequently, for complex aortic plaque (CAP) [2]. However, in our study, obese patients were excluded due to the suboptimal visualization of the AA using US in this population. Therefore, in this important patient group, assessment of AA-CAP using alternative imaging modalities such as CT and MR could have been performed. Furthermore, measurements obtained by US could have been validated against these imaging techniques. Despite the findings of our study, CT, MR, and TOE remain the preferred modalities for the evaluation of CAP. Our results cannot be directly compared with these imaging techniques; however, abdominal US may be considered a simple, inexpensive, noninvasive, and repeatable imaging modality for the assessment of AA-CAP. Another important limitation of our study is the lack of evaluation of CAP in the ascending aorta, as well as the absence of assessment of carotid plaque. Conclusion According to the results of our study, AA–CAP is present at a considerable rate (14.2%) in patients with AF and is closely associated with the CHA₂DS₂-VA score. Approximately 2% of patients exhibited isolated AA-CAP in the absence of other CHA₂DS₂-VA score components. Furthermore, assessment of AA–CAP in AF patients without a history of vascular disease may allow for a more objective and accurate calculation of the CHA₂DS₂-VA score. In patients followed for AF, evaluation of AA–CAP using abdominal US—a simple, inexpensive, noninvasive, and repeatable imaging modality—may be feasible in routine clinical practice. However, to establish more robust and definitive clinical recommendations, prospective, randomized, multicenter studies including larger patient populations are warranted. Acknowledgements Not applicable. Abbreviations Complex aortic plaque Abdominal aortic Ultrasonography Atrial fibrillation Hypertension Diabetes mellitus Coronary artery disease Peripheral vascular disease Transesophageal echocardiography Cardiovascular computed tomography Cardiovascular magnetic resonance Transthoracic echocardiography Standard deviation Receiver operating characteristic Heart failure Authors’ contributions AB: Conceptualized the study, data collection and analysis. FK: Data collection. YD: Data collection. HES: Drafting of the manuscript. MLA: Writing – review and editing. MK: Supervison. All authors reviewed the manuscript. All authors consented and contributed to the manuscript. Funding No funding. Data availability All data generated and analyzed during this study are included in this published article. The data presented in the article may be requested by consulting the correspondence author. Declarations Ethics approval and consent to participate This study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Ethics Committee of Adana City Hospital (approval number: 1027). Consent for publication All authors reviewed and approved the final version for publication. Competing interests The authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement All data generated and analyzed during this study are included in this published article. The data presented in the article may be requested by consulting the correspondence author.